Latest Orthopaedics News

Orthocell’s nerve repair device Remplir is being adopted in Australia for nerve-sparing prostate cancer surgeries, aiming to reduce erectile dysfunction and urinary incontinence post-operation. This development could significantly expand Remplir’s market reach globally.

Cambium Bio has struck a licensing deal with Keke Medtech to commercialise its fibrin biologic in dental applications, unlocking new markets and non-dilutive funding.

Osteopore Limited reported a 6% increase in revenue to $1.56 million for the half-year ended June 2025, alongside a slight rise in net loss driven by expanded product development and compliance costs. The company secured key regulatory approvals and broadened its distribution footprint in Asia and the US.

Paragon Care Limited reported solid FY25 results with revenue climbing to $3.61 billion and underlying EBITDA rising 3%, driven by successful integration and expansion into new healthcare segments.

Desane Group Holdings Limited reported a strong FY25 with net profit after tax doubling to $3.3 million, supported by a $6.2 million uplift in property valuations and key lease extensions securing future rental income.

Osteopore Limited has won tender bids to supply its innovative orthopaedic implants to two major public hospitals in Vietnam, marking a significant step in its Asia Pacific expansion.

Osteopore Limited has posted a record AUD 835K revenue in Q2 CY25, driven by strong APAC sales and new European market access following EU MDR clearance. The company also advances clinical trials and refreshes key distribution channels.

Osteopore Limited has gained Swiss market approval for its 3D-printed bioresorbable implants under the EU Medical Device Regulation, completing its European product portfolio and strengthening its partnership with Zimmer Biomet.

ReNerve Limited has entered a strategic partnership with Berkeley Biologics to develop and commercialise two new tissue-based product ranges, aiming to expand its footprint in the US surgical market by the end of 2025.

Desane Group Holdings has secured a seven-year lease extension with Signature Orthopaedics at its Lane Cove property, guaranteeing $5 million in rental income through 2032. This deal reinforces Desane’s strategy to maintain stable medium-term cash flows.

Osteopore Limited reported a robust 26% quarter-on-quarter revenue increase in Q1 CY25, bolstered by a key Singapore subsidy listing and a strategic pivot away from its dental project to sharpen commercial focus.

EBOS Group Limited’s interim results for H1 2025 reveal a notable decrease in revenue and profit compared to the prior year, yet the company maintains its interim dividend, signaling confidence despite headwinds.